82 GlaxoSmithKline Operating and financial review and prospects Operating and financial review and prospects GlaxoSmithKline 83 Selected financial data UK US GAAP Merger items, restructuring costs and disposal of businesses Earnings Growth profit and loss account 2003 2002 2001 2000 1999 2002 2001 CER% % m m m m m Merger and integration items represent those items which have Earnings m 3,915 3,053 35 28 arisen as a result of the merger of Glaxo Wellcome and SmithKline Amounts in accordance with UK GAAP Basic earnings per share 66.2p 50.3p 38 32 Beecham and the acquisition of Block Drug.
Restructuring costs Turnover 21,441 21,212 20,489 18,079 16,796 Basic earnings per ADS $1.99 $1.45 38 32 arise from the merger and acquisition and from manufacturing Operating profit 6,392 5,551 4,734 4,729 4,343 restructuring programmes that had already been agreed by Glaxo profit before taxation 6,329 5,506 4,517 6,029 4,236 Adjusted earnings m 4,627 4,383 11 6 Wellcome and SmithKline Beecham before the date of the merger.
Earnings 4,484 3,915 3,053 4,106 3,077 Adjusted earnings per share 78.3p 72.3p 13 8 These items by their nature are considered to be outside the Basic earnings per share 77.2p 66.2p 50.3p 67.7p 50.3p Adjusted earnings per ADS $2.35 $2.08 13 8 normal business expenditure of GlaxoSmithKline and not expected Diluted earnings per share 77.0p 66.0p 49.9p 66.9p 49.9p Weighted average number to occur on a regular basis.
of shares millions 5,912 6,064 Weighted average number of shares in issue: Basic 5,806 5,912 6,064 6,065 6,118 The key items in 2002 are discussed below.
Adjusted earnings and adjusted earnings per share are presented Diluted 5,824 5,934 6,116 6,134 6,171 above in order to illustrate business performance which is the Merger and manufacturing restructuring Dividends per GlaxoSmithKline share pence primary performance measure used by management.
Adjusted GlaxoSmithKline has made good progress with its merger and GlaxoSmithKline shareholder 41.0p 40.0p 39.0p earnings increased by 11 per cent.
Adjusted earnings per share manufacturing restructuring plans and remains on track to deliver Glaxo Wellcome shareholder 38.0p 37.0p increased 13 per cent, reecting the reduction in the weighted forecast total annual merger and manufacturing restructuring SmithKline Beecham shareholder 29.66p 26.69p average number of shares resulting from the Groups share savings of 1.8 billion by 2003, excluding benets from the Block buy-back programme.
The interest cost of this programme also Drug acquisition.
The estimated cost of achieving this remains Dividends are expressed in terms of a GlaxoSmithKline share.
around 3.8 billion, of which 3.4 billion had been charged by Amounts in accordance with US GAAP 31st December 2002.
At actual rates of exchange business performance EPS increased Turnover 21,117 21,212 20,489 9,559 8,490 eight per cent compared with 13 per cent in CER terms.
The Costs of 972 million were incurred in the year in respect of Net income loss 2,420 413 143 5,228 913 adverse currency impact on EPS of five per cent in the year merger and manufacturing restructuring.
After tax relief of Basic net income loss per share pence 41.7p 7.0p 2.4 p 145.6 p 25.2p reected the significant weakening of the US dollar relative to 249 million, the net charge was 723 million.
The costs in 2002 Diluted net income loss per share pence 41.6p 7.0p 2.4 p 145.6 p 25.1p 2001 and compares with a three per cent adverse currency impact include severance, asset write-downs, professional fees and site on sales.
This difference principally arises from a different mix of The information below presents US GAAP net income loss and net income loss per share as if the results for the years ended closure.
currencies in profits compared with sales.
31st December 1999 to 2001 were adjusted to reverse the amortisation expense for goodwill and indefinite-lived intangible assets, that is, as if SFAS 142 had also applied in those years.
Block Drug Company, Inc. Taken together with other expenses, taxation and product GlaxoSmithKline acquired Block Drug in January 2001.
The costs divestments this resulted in EPS of 66.2 pence compared with Adjusted net income loss 1,456 4,658 1,476 incurred in integrating this business were 60 million in 2002 50.3 pence in 2001 and a diluted EPS of 66.0 pence compared Adjusted basic net income loss per share pence 24.0p 129.7 p 40.8p including redundancies, asset write-downs and site closures.
Merger and manufacturing restructuring Adjusted diluted net income loss per share pence 23.8p 129.7 p 40.6p costs were lower in 2002 than in 2001 and as a result, the sterling Disposal of businesses based growth in EPS of 32 per cent was signicantly higher than Balance sheet The profit on disposal of businesses in 2002 of 21 million reects the CER based growth in business performance EPS despite the m m m m m the final settlements regarding merger related product disposals overall negative impact of currencies in 2002.
Amounts in accordance with UK GAAP and the disposal of the Healthcare Services businesses in 1999.
Total assets 23,975 22,327 22,343 21,999 19,162 Dividend Net assets 8,465 7,388 8,252 8,834 6,534 Taxation 2002 2001 m m The Board declared a fourth interim dividend of 13 pence per Equity shareholders funds 7,720 6,581 7,390 7,590 5,391 share making a total for the year of 40 pence per share.
This Business performance 1,760 1,655 Amounts in accordance with US GAAP compares with a dividend of 39 pence per share for 2001.
Merger, restructuring and disposal Total assets 56,400 57,671 61,341 65,786 13,901 Net assets 34,861 35,729 40,969 46,239 7,281 of subsidiaries 299 322 Shareholders equity 34,116 34,922 40,107 44,995 7,230 Total 1,461 1,333 Exchange rates The charge for taxation on business performance profit of 1,760 million represents an effective tax rate of 27.0 per cent.
As a guide to holders of ADRs, the following tables set out, for the periods indicated, information on the exchange rate of US dollars This represents an increase compared with the effective rate for for sterling as reported by the Federal Reserve Bank of New York noon buying rate.
2001 which was 26.8 per cent, as restated for the implementation Average 1.63 1.51 1.44 1.51 1.61 of FRS 19 Deferred Tax.
The average rate for the year is calculated as the average of the noon buying rates on the last day of each month during the year.
The credit for taxation on merger and restructuring items Feb Jan Dec Nov Oct Sept amounting to 299 million reects the estimated actual tax rate 2004 2004 2003 2003 2003 2003 applicable to the transactions in the territories in which they arise.
84 GlaxoSmithKline GlaxoSmithKline 85 Financial statements This section comprises the Directors statements of responsibility, the Independent Auditors report on the Financial statements, the Financial statements consisting of the principal Financial statements and supporting notes.
86 Directors statements of responsibility 87 Independent Auditors report Financial statements 88 Consolidated statement of profit and loss 88 Consolidated statement of total recognised gains and losses 90 Consolidated statement of cash ow 92 Consolidated balance sheet 92 Reconciliation of movements in equity shareholders funds 93 Company balance sheet Notes to the financial statements 94 1.
New accounting policies and future requirements 97 4.
Merger of Glaxo Wellcome and SmithKline Beecham 98 6.
Merger items, restructuring costs and divested businesses 101 8.
Joint ventures and associated undertakings 103 11.
Provisions for liabilities and charges 109 24.
Share capital and share premium account 112 28.
Financial instruments and related disclosures 126 33.
Reconciliation to US accounting principles 146 37.
Principal Group companies 86 GlaxoSmithKline GlaxoSmithKline 87 Directors statements of responsibility Independent Auditors report to the members of GlaxoSmithKline plc Directors statement of responsibility in relation to the Internal control We have audited the Financial statements which comprise the Basis of audit opinion Financial statements consolidated statement of profit and loss, consolidated statement The Board, through the Audit Committee, has reviewed the We conducted our audit in accordance with Auditing Standards of total recognised gains and losses, consolidated statement of The Directors are: assessment of risks and the internal control framework that issued by the United Kingdom Auditing Practices Board.
An audit cash ow, consolidated and company balance sheets and the operates in GlaxoSmithKline and has considered the effectiveness includes examination, on a test basis, of evidence relevant responsible for ensuring the maintenance of proper accounting related notes, which have been prepared under the historical cost of the system of internal control in operation in the Group for the to the amounts and disclosures in the Financial statements and records, which disclose with reasonable accuracy the financial convention and the accounting policies set out in the statement year covered by this report and up to the date of its approval by the auditable part of the Directors remuneration report.
It also position of the Group at any time and from which financial of accounting policies.
We have also audited the disclosures the Board of Directors.
includes an assessment of the significant estimates and judgements statements can be prepared to comply with the Companies required by Part 3 of Schedule 7A to the Companies Act 1985 made by the Directors in the preparation of the Financial Act 1985 contained in the Directors remuneration report the auditable The 1998 Combined Code statements, and of whether the accounting policies are appropriate part.
required by law to prepare financial statements for each to the companys and Groups circumstances, consistently applied The Board considers that GlaxoSmithKline plc applies the principles financial period which give a true and fair view of the state and adequately disclosed.
of the 1998 Combined Code, as described under Corporate Respective responsibilities of Directors and Auditors of affairs of the company and the Group as at the end of governance pages 33 to 42, and has complied with the We planned and performed our audit so as to obtain all the the financial period and of the profit or loss for that period The Directors responsibilities for preparing the Annual Report, requirements of the 1998 Combined Code, with the exception information and explanations which we considered necessary in the Directors remuneration report and the Financial statements in responsible also for ensuring the operation of systems of of the Senior Independent Director where the companys position order to provide us with sufficient evidence to give reasonable accordance with applicable United Kingdom law and accounting internal control and for taking reasonable steps to safeguard is described under Corporate governance and the provisions assurance that the financial statements and the auditable part standards are set out in the statement of Directors responsibility.
the assets of the Group and for preventing and detecting relating to the Executive Directors service contracts and pension of the Directors remuneration report are free from material fraud and other irregularities.
arrangements, where the companys position is described in the Our responsibility is to audit the Financial statements and the misstatement, whether caused by fraud or other irregularity or Remuneration Report.
auditable part of the Directors remuneration report in accordance error.
In forming our opinion we also evaluated the overall The Financial statements for the year ended 31st December 2003, with relevant legal and regulatory requirements and United adequacy of the presentation of information in the Financial comprising principal statements and supporting notes, are set out As required by the Listing Rules of the Financial Services Authority, Kingdom Auditing Standards issued by the Auditing Practices statements.
in Financial statements pages 88 to 148 of this report.
the auditors have considered the Directors statement of Board.
This report, including the opinion, has been prepared for compliance in relation to those points of the 1998 Combined The Directors confirm that suitable accounting policies have been and only for the companys members as a body in accordance with Opinion Code which are specified for their review.
consistently applied in the preparation of the Financial statements, Section 235 of the Companies Act 1985 and for no other purpose.
In our opinion: supported by reasonable and prudent judgements and estimates We do not, in giving this opinion, accept or assume responsibility Annual Report as necessary: applicable accounting standards have been followed, for any other purpose or to any other person to whom this report the Financial statements give a true and fair view of the state and the Financial statements have been prepared on the going The Annual Report for the year ended 31st December 2003, is shown or into whose hands it may come save where expressly of affairs of the company and the Group at 31st December concern basis.
comprising the Report of the Directors, the Remuneration Report, agreed by our prior consent in writing.
2003 and of the profit and cash ows of the Group for the the Financial statements and additional information for investors, year then ended: The responsibilities of the auditors in relation to the Financial We report to you our opinion as to whether the Financial has been approved by the Board of Directors and signed on its the Financial statements have been properly prepared in statements are set out in the Independent Auditors report statements give a true and fair view and whether the Financial behalf by accordance with the Companies Act 1985: and page 87 opposite.
statements and the auditable part of the Directors remuneration those parts of the Remuneration Report required by Part 3 of report have been properly prepared in accordance with the The Financial statements for the year ended 31st December 2003 Schedule 7A to the Companies Act 1985 have been properly Companies Act 1985.
We also report to you if, in our opinion, are included in the Annual Report 2003, which is published in prepared in accordance with the Companies Act 1985. the report of the Directors is not consistent with the Financial hard-copy printed form and on the website.
The Directors are statements, if the company has not kept proper accounting responsible for the maintenance and integrity of the Annual records, if we have not received all the information and Report on the website in accordance with UK legislation governing explanations we require for our audit, or if information specified the preparation and dissemination of financial statements.
Access Sir Christopher Hogg by law regarding Directors remuneration and transactions is not to the website is available from outside the UK, where comparable Chairman disclosed.
3rd March 2004 We read the other information contained in the Annual Report  LLP Directors remuneration and consider the implications for our report if we become aware Chartered Accountants and Registered Auditors of any apparent misstatements or material inconsistencies with the Embankment Place The Remuneration Report pages 43 to 58 of this report sets Financial statements.
The other information comprises only the London, England out the remuneration policies operated by GlaxoSmithKline and Financial summary, description of business, unauditable part of the 3rd March 2004 disclosures on Directors remuneration and other disclosable Directors remuneration report, the joint statement by the Chairman information relating to Directors and ofcers and their interests.
and the Chief Executive officer, the operating and financial review It has been prepared in accordance with the Companies Act 1985, and prospects and the corporate governance statement.
as amended by the Directors Remuneration Report Regulations We review whether the corporate governance statement reects 2003 and complies with Section B of the 1998 Combined Code.
the companys compliance with the seven provisions of the Combined Code issued in June 1998 specified for our review by Going concern basis the Listing Rules of the Financial Services Authority, and we report After making enquiries, the Directors have a reasonable if it does not.
We are not required to consider whether the Boards expectation that the Group and company have adequate resources statements on internal control cover all risks and controls, or to to continue in operational existence for the foreseeable future.
form an opinion on the effectiveness of the companys or Groups For this reason, they continue to adopt the going concern basis corporate governance procedures or its risk and control in preparing the Financial statements.
Consolidated statement of total recognised gains and losses for the year ended 31st December 2003 2003 2002 2001 m m m profit attributable to shareholders 4,484 3,915 3,053 Exchange movements on overseas net assets 37 154 151 Unrealised gains on equity investments 7 7 Tax on exchange movements and unrealised gains 69 67 Total recognised gains and losses 4,459 3,701 2,902 90 GlaxoSmithKline Consolidated statement of cash ow GlaxoSmithKline 91 Consolidated statement of cash ow for the year ended 31st December 2003 Reconciliation of operating profit to operating cash ows 2003 2002 2001 Analysis of cash ows Notes 2003 2002 2001 Notes m m m m m m Operating profit 6,392 5,551 4,734 Returns on investment and servicing of finance Depreciation 773 764 761 Interest received 65 83 134 Impairment and assets written off 250 288 178 Interest paid 197 215 196 Amortisation of goodwill and intangible xed assets 87 72 50 Dividends paid to minority shareholders 84 85 91 Loss on sale of tangible xed assets 26 99 Dividends paid on preference shares 15 20 38 profit on sale of equity investments 89 46 118 231 237 191 Increase decrease in stocks 76 2 252 Increase in trade and other debtors 552 72 77 Capital expenditure and financial investment Decrease increase in trade and other creditors 69 459 601 Purchase of tangible xed assets 869 1,044 1,115 Increase in provisions 260 256 144 Sale of tangible xed assets 46 59 65 Other 29 41 93 Purchase of intangible assets 193 182 196 Merger transaction costs paid 24 Sale of intangible assets 6 Product divestments 1 30 Net cash inow from operating activities 7,005 7,255 6,507 Purchase of own shares for employee share options and awards 795 Proceeds from own shares for employee share options 26 58 194 Cash ow statement Purchase of equity investments 63 75 47 Sale of equity investments 125 65 139 Net cash inow from operating activities 7,005 7,255 6,507 928 1,120 1,779 Dividends from joint ventures and associated undertakings 1 2 Returns on investment and servicing of finance 231 237 191 Acquisitions and disposals 31 Taxation paid 1,917 1,633 1,717 Purchase of businesses 12 21 848 Capital expenditure and financial investment 928 1,120 1,779 Cash acquired with subsidiary 45 Acquisitions and disposals 31 12 20 657 Disposal of businesses 3 6 66 Equity dividends paid 2,333 2,327 2,325 Investment in joint ventures and associated undertakings 3 5 44 Net cash inow outow before management of liquid resources and nancing 1,585 1,920 162 Disposal of interests in associates 124 Management of liquid resources 1,336 52 994 12 20 657 Financing 276 1,567 1,444 Decrease increase in cash in the year 27 405 612 Financing Issue of share capital 27 41 56 144 Redemption of preference shares issued by a subsidiary 457 Reconciliation of net cash ow to movement in net debt Share capital purchased for cancellation 980 2,220 1,274 Other nancing cash ows 82 135 144 Net debt at beginning of year 2,335 2,101 611 Increase in long-term loans 1,046 1,094 973 Decrease increase in cash in the year 27 405 612 Repayment of long-term loans 23 89 112 Cash inow outow from management of liquid resources 1,336 52 994 Net repayment of short-term loans 442 542 860 Net increase in long-term loans 1,023 1,005 861 Net repayment of obligations under finance leases 1 2 Net repayment of short-term loans 442 542 860 Net repayment of obligations under finance leases 1 2 276 1,567 1,444 Net non-cash funds of subsidiary undertakings acquired 4 56 Exchange adjustments 37 121 59 Analysis of changes in net debt At 31.12.03 Cash ow Other Exchange At 1.1.
03 m m m m m Other non-cash movements 4 Cash at bank 962 54 36 1,052 Movement in net debt 687 234 1,490 Overdrafts 155 27 11 193 Net debt at end of year 25 1,648 2,335 2,101 807 27 25 859 Debt due within one year: Commercial paper 836 449 1 1,284 Eurobonds and Medium-Term Notes 383 414 31 Other 78 7 3 74 1,297 442 415 34 1,358 Debt due after one year: Eurobonds, Medium-Term Notes and private nancing 3,617 1,027 411 53 3,054 Other 34 4 38 3,651 1,023 411 53 3,092 Management of liquid resources: Liquid investments 2,493 1,336 99 1,256 Net debt 1,648 728 4 37 2,335 For further information on significant changes in net debt see Note 25 Net debt.
92 GlaxoSmithKline GlaxoSmithKline 93 Consolidated balance sheet Company balance sheet at 31st December 2003 at 31st December 2003 2003 2002 2003 2002 Notes m m Notes m m Shares in subsidiary companies at cost 37 17,612 17,612 Goodwill 15 143 171 Fixed assets 17,612 17,612 Other intangible assets 16 1,697 1,637 1,840 1,808 Amounts owed by Group undertakings 2,969 1,412 Tangible assets 17 6,441 6,649 Taxation 52 66 Investments 18 3,069 3,121 Cash at bank 8 Fixed assets 11,350 11,578 Current assets 3,029 1,478 Equity investments 19 164 161 Dividends payable 14 1,331 1,289 Stocks 20 2,109 2,080 Amounts owed to Group undertakings 8,578 5,192 Debtors 21 6,897 6,200 Creditors: amounts due within one year 9,909 6,481 Liquid investments 25 2,493 1,256 Net current liabilities 6,880 5,003 Cash at bank 25 962 1,052 Net assets 10,732 12,609 Current assets 12,625 10,749 Loans and overdrafts 25 1,452 1,551 Capital and reserves Other creditors 22 7,145 7,257 Called up share capital 27 1,487 1,506 Creditors: amounts due within one year 8,597 8,808 Share premium account 27 264 224 Net current assets 4,028 1,941 Other reserves 29 76 56 profit and loss account 29 8,905 10,823 Total assets less current liabilities 15,378 13,519 Equity shareholders funds 10,732 12,609 Loans 25 3,651 3,092 Other creditors 22 232 206 Creditors: amounts due after one year 3,883 3,298 Provisions for liabilities and charges 23 3,030 2,833 Approved by the Board Net assets 8,465 7,388 Sir Christopher Hogg Capital and reserves Chairman Called up share capital 27 1,487 1,506 3rd March 2004 Share premium account 27 264 224 Other reserves 29 1,925 1,905 profit and loss account 29 4,044 2,946 Equity shareholders funds 7,720 6,581 Non-equity minority interests 28 503 559 Equity minority interests 242 248 Capital employed 8,465 7,388 Approved by the Board Sir Christopher Hogg Chairman 3rd March 2004 Reconciliation of movements in equity shareholders funds for the year ended 31st December 2003 2003 2002 Notes m m Equity shareholders funds at beginning of year 6,581 7,390 Total recognised gains and losses for the year 4,459 3,701 Dividends 14 2,374 2,346 Share capital issued 41 56 Share capital purchased and cancelled 980 2,220 Exchange movements on goodwill written off to reserves 7 Equity shareholders funds at end of year 7,720 6,581 94 GlaxoSmithKline Notes to the financial statements GlaxoSmithKline 95 Notes to the financial statements 1 Presentation of the Financial statements Additional information in accordance with the requirements of 2Accounting policies Foreign currency transactions US generally accepted accounting principles US GAAP is included Foreign currency transactions by Group companies are booked Description of business Consolidation in the Notes to the Financial statements.
In Note 36 a statement in local currency at the exchange rate ruling on the date of GlaxoSmithKline is a major global healthcare group which is The consolidated Financial statements include: of differences, and reconciliations of net income and shareholders transaction, or at the forward rate if hedged by a forward engaged in the creation and discovery, development, manufacture equity, between UK and US GAAP are provided.
the assets and liabilities, and the results and cash ow, of the exchange contract.
Foreign currency assets and liabilities are and marketing of pharmaceutical products, including vaccines, company and its subsidiary undertakings, including Employee translated into local currency at rates of exchange ruling at the over-the-counter OTC medicines and health-related consumer Presentation of statement of profit and loss Share Ownership Trusts ESOTs balance sheet date, or at the forward rate.
GlaxoSmithKlines principal pharmaceutical products A columnar presentation has been adopted in the statement the Groups share of the net assets and results of joint ventures are included in trading profit.
include medicines in the following therapeutic areas: of profit and loss in order to illustrate underlying business and associated undertakings.
central nervous system, respiratory, anti-virals, anti-bacterials, performance as this is the primary measure used by management.
Revenue vaccines, oncology and emesis, metabolic, cardiovascular and The Financial statements of undertakings consolidated are made For this purpose certain items are identied separately and are Revenue is recognised in the profit and loss account when goods urogenital.
These comprise: merger and are supplied to external customers against orders received.
In integration items, including product divestments: costs relating to Undertakings in which the Group has a material interest are certain limited cases, the customer collects the goods and revenue Financial period previously announced manufacturing and other restructuring, and accounted for as subsidiaries where the Group exercises dominant is recognised when title and risk of loss passes.
Turnover represents These Financial statements cover the financial year from the effect of disposals of subsidiaries.
Management believes that inuence, as joint ventures where the Group exercises joint control net invoice value after the deduction of discounts given at the 1st January to 31st December 2003, with comparative gures for exclusion of these items provides a better reection of the way in and as associates where the Group can exercise significant point of sale, and accruals for estimated future rebates and the financial years from 1st January to 31st December 2002 and which the business is managed and gives an indication of the inuence.
The methodology and assumptions used to estimate 1st January to 31st December 2001. performance of the Group in terms of those elements of revenue rebates and returns are monitored regularly in the light of Interests acquired in undertakings are consolidated from the and expenditure which local management is able to inuence.
historical information and past experience.
Turnover also includes Composition of the Group effective date of acquisition and interests sold are consolidated co-promotion income where the Group records its share of the A list of the subsidiary and associated undertakings which, in the Trading profit reects turnover less: cost of sales, comprising up to the date of disposal.
revenue but with no related cost of sales.
Value added tax and opinion of the Directors, principally affected the amount of profit costs of manufacture and external royalties: selling, general and Transactions and balances between subsidiary undertakings are other sales taxes are excluded from revenue.
or the net assets of the Group is given in Principal Group administrative expenditure, comprising the costs of selling, eliminated: no profit is taken on sales between subsidiary companies, Note 37. distribution and medical support of currently marketed products undertakings or sales to joint ventures and associated undertakings Expenditure and the costs of administration: and the costs of research and until the products are sold to customers outside the Group.
Expenditure is recognised in respect of goods and services received Composition of financial statements development to create future products for sale.
when supplied in accordance with contractual terms.
Provision is The consolidated Financial statements are drawn up in accordance Goodwill arising on the acquisition of interests in subsidiary made when an obligation exists for a future liability in respect of a with UK generally accepted accounting principles UK GAAP and Accounting convention undertakings, joint ventures and associated undertakings, past event and where the amount of the obligation can be reliably with UK accounting presentation.
The Financial statements have been prepared using the historical representing the excess of the purchase consideration over the estimated.
Advertising and promotion expenditure is charged to cost convention.
Groups share of the separable net assets acquired, is capitalised The Financial statements comprise: the profit and loss account as incurred.
Shipment costs on interas a separate item in the case of subsidiary undertakings and as company transfers are charged to cost of sales: distribution costs Consolidated statement of profit and loss Accounting standards part of the cost of investment in the case of joint ventures and on sales to customers are included in selling, general and Consolidated statement of total recognised gains and losses The Financial statements comply with all applicable UK accounting associated undertakings.
Goodwill is denominated in the currency administrative expenditure.
Restructuring costs are recognised in Consolidated statement of cash ow standards.
in which the acquisition is made and nanced.
In the case of respect of the direct expenditures of a business reorganisation Consolidated balance sheet acquisitions prior to 1998, goodwill was written off against where the plans are sufciently detailed and well advanced, and Reconciliation of movements in equity shareholders funds Accounting principles and policies reserves: on a subsequent disposal of assets from such acquisitions, where appropriate communication to those affected has been Company balance sheet The preparation of the Financial statements in conformity with any related goodwill is removed from consolidated reserves and undertaken at the balance sheet date.
Notes to the financial statements.
generally accepted accounting principles requires management to charged to the consolidated profit and loss account.
make estimates and assumptions that affect the reported amounts As permitted by Section 230 of the Companies Act 1985, the The Groups interests in its joint ventures are accounted for using Research and development of assets and liabilities and disclosure of contingent assets and profit and loss account of the company is not presented.
The Groups interests in its associated Research and development expenditure is charged to the profit liabilities at the date of the Financial statements and the reported undertakings are accounted for using the equity method.
and loss account in the period in which it is incurred.
Tangible The consolidated statement of total recognised gains and losses amounts of revenues and expenses during the reporting period.
xed assets used for research and development are depreciated includes: Actual results could differ from those estimates.
Deferred taxation relief on unrealised intra-Group profit is in accordance with the Groups policy.
accounted for only to the extent that it is considered recoverable.
the realised profit attributable to shareholders as reected The Financial statements have been prepared in accordance with in the consolidated statement of profit and loss the companys accounting policies approved by the Board and Assets and liabilities of overseas subsidiary and associated Environmental expenditure the unrealised gain or loss in the value of the Groups described in Note 2. undertakings and joint ventures including related goodwill, are Environmental expenditure related to existing conditions resulting overseas net assets, less related foreign currency borrowings, translated into sterling at rates of exchange ruling at the balance from past or current operations and from which no current or attributable to currency movements over the period sheet date.
The results and cash ows of overseas subsidiary and future benefit is discernible is charged to the profit and loss tax on the above items.
associated undertakings and joint ventures are translated into account.
The Group determines its liability on a site-by-site basis sterling using average rates of exchange.
Exchange adjustments and records a liability at the time when it is probable and can be The reconciliation of movements in equity shareholders funds arising when the opening net assets and the profits for the year reasonably estimated.
This liability includes the Groups own comprises the items contributing to the increase or decrease over retained by overseas subsidiary and associated undertakings and portion of the costs and also a portion of other potentially the period in shareholders funds.
Such items include: joint ventures are translated into sterling, less exchange differences responsible parties costs when it is probable that they will not be the total recognised gains and losses for the period arising on related foreign currency borrowings, are taken directly able to satisfy their respective shares of the clean-up obligation.
dividends paid and proposed to reserves and reported in the statement of total recognised When recoveries of reimbursements are virtually certain they are the proceeds of shares issued during the period gains and losses.
the cost of shares purchased for cancellation under the In translating into sterling, assets, liabilities, results and cash ows share buy-back programme Pensions and post-retirement benets of overseas subsidiary and associated undertakings and joint changes to goodwill, arising on acquisitions prior to The cost of providing pensions and other employee post-retirement ventures reported in currencies of hyper-inationary economies, 1st January 1998, which has been set directly against reserves.
benets is charged to the consolidated profit and loss account on a adjustments are made to reect current price levels.
Any loss on systematic and rational basis, based on actuarial assumptions, over net monetary assets is charged to the consolidated profit and loss the period during which benefit is derived from employees services.
Any difference between this charge and the contributions paid is included as an asset or liability in the consolidated balance sheet.
96 GlaxoSmithKline Notes to the financial statements Notes to the financial statements GlaxoSmithKline 97 2Accounting policies continued Prior to 1998, acquired minor brands and similar intangibles were 2Accounting policies continued Gains and losses on foreign exchange contracts designated as eliminated in the Group balance sheet against reserves in the year hedges of forecast foreign exchange transactions are deferred and Legal and other disputes Investments in joint ventures and associates of acquisition.
included in the measurement of the related foreign currency Provision is made for the anticipated settlement costs and legal Investments in joint ventures and associated undertakings are transactions in the period they occur.
Gains and losses on balance and other expenses associated with claims received and legal and carried in the consolidated balance sheet at the Groups share Tangible xed assets sheet hedges are accrued and are taken directly to reserves, except other disputes against the Group where a reasonable estimate can of their net assets at date of acquisition and of their postTangible xed assets are stated at cost less provisions for that forward premium discounts are recognised as interest over the be made of the likely outcome of the dispute.
No provision is acquisition retained profits or losses together with any goodwill depreciation or impairment.
The costs of acquiring and developing life of the contracts.
made for unasserted claims or where an obligation exists under a arising on the acquisition, net of amortisation.
computer software for internal use and internet sites for external dispute but it is not possible to make a reasonable estimate.
Costs Interest differentials under interest swap agreements are recognised use are capitalised as a tangible xed asset where the software or associated with claims made by the Group against third parties are Stocks in the profit and loss account by adjustment of interest expense site supports a significant business system and the expenditure charged to the profit and loss account as they are incurred.
Stocks are included in the financial statements at the lower of cost over the life of the agreement.
leads to the creation of a durable asset.
including manufacturing overheads, where appropriate and net Employee share plans Depreciation is calculated to write off the cost of tangible xed realisable value.
Cost is generally determined on a first in, first Debt instruments Incentives in the form of shares are provided to employees under assets, excluding freehold land, in equal annual instalments over out basis.
Debt instruments are stated at the amount of net proceeds share option and share award schemes.
In respect of award their expected useful lives.
The normal expected useful lives of the adjusted to amortise the issue cost of debt evenly over the term schemes and certain share option grants, the company provides major categories of tangible xed assets are reviewed annually Taxation of the debt.
finance to ESOTs to purchase company shares on the open market and are: The Group accounts for taxation which is deferred or accelerated to meet the companys obligation to provide shares when by reason of timing differences which have originated but not 3New accounting policies and future requirements Freehold buildings 20 to 50 years employees exercise their option or award: any excess of the reversed by the balance sheet date.
Deferred tax assets are only In December 2003 the Urgent Issues Task Force issued Abstract Leasehold land and The shorter of lease term and 50 purchase price of the shares above the exercise price of the options recognised to the extent that they are considered recoverable 38 and amended Abstract 17, both relating to the accounting for buildings years and awards is charged to the profit and loss account over the against future taxable profits.
Deferred tax on the retained and presentation of ESOTs.
These requirements are mandatory for Plant and machinery 10 to 20 years periods of service in respect of which the options and awards are earnings of overseas subsidiaries is only provided when there is a 2004 reporting and will require the shares held by the ESOTs to Fixtures and equipment 3 to 10 years granted.
In respect of other share option grants, share options binding commitment to distribute past earnings in future periods.
be shown as a deduction in arriving at shareholders funds.
The ERP systems software 7 years when exercised are accounted for as share issues at exercise price.
Deferred tax is measured at the average tax rates that are expected charge to the profit and loss account for employee share options Other computer software 3 to 5 years Additional employer costs in respect of options and awards are to apply in the periods in which the timing differences are will be restricted to the intrinsic loss, the difference between the charged to the profit and loss account over the periods of service.
Deferred tax liabilities and assets are not market price and exercise price, at the date of grant.
ERP systems software generally involves significant customisation Assets and liabilities of the ESOTs are included in the Group discounted.
prior to implementation and is expected to have a useful economic In June 2002, the Council of the European Union adopted a balance sheet.
Costs of running the ESOTs are charged to the profit life of seven years, rather than the maximum five years of other Regulation requiring listed companies in its Member States to and loss account.
Shares held by the ESOTs are accounted for as Current asset investments computer software.
On disposal of a tangible xed asset, the cost prepare their consolidated financial statements in accordance with xed asset investments held at cost less a provision to recognise Current asset investments are stated at the lower of cost and net and related accumulated depreciation are removed from the International Financial Reporting Standards IFRS from 2005.
The any shortfall in the proceeds receivable from employees on exercise realisable value.
financial statements and the net amount, less any proceeds, is first GlaxoSmithKline Annual Report prepared under IFRS will be unless there is deemed to be a permanent impairment in value.
taken to the consolidated profit and loss account.
In the case of securities acquired at a significant premium or that for the year ending 31st December 2005.
The first financial discount to maturity value, and intended to be held to redemption, results announcement prepared in accordance with IFRS will be Goodwill Leases cost is adjusted to amortise the premium or discount over the life that for the first quarter of 2005.
Goodwill is stated at cost less a provision for amortisation.
Leasing agreements which transfer to the Group substantially all to maturity of the security.
Floating rate bonds are stated at cost.
Amortisation is calculated to write off the cost in equal annual The Groups project to convert its financial reporting from UK the benets and risks of ownership of an asset are treated as Interest income is taken to the profit and loss account on a instalments over its expected useful life.
The useful life is not GAAP to IFRS is progressing well.
A training programme has been finance leases, as if the asset had been purchased outright.
normally expected to exceed 20 years.
rolled out to all finance staff worldwide and preparations for the assets are included in tangible xed assets and the capital element Equity investments are included as current assets when regarded collection of historical data, which will provide the comparative of the leasing commitments is shown as obligations under finance Intangible xed assets as available for sale.
information under IFRS in 2005, are well advanced.
Assets held under finance leases are depreciated over the Intangible assets are stated at cost less a provision for amortisation.
shorter of the lease terms and the useful lives of the assets.
The Derivative financial instruments 4 Exchange rates interest element of the lease rental is charged against profit.
Acquired licences, patents, know-how and marketing rights are The Group does not hold or issue derivative financial instruments All other leases are operating leases and the annual rentals are amortised over their estimated useful lives in equal instalments, The Group uses the average of exchange rates prevailing during for trading purposes.
charged against profit on a straight-line basis over the lease term.
Items capitalised are restricted to the period to translate the results and cash ows of overseas those related to specic compounds or products which are being Derivative financial instruments are used to manage exposure to subsidiaries, joint ventures and associated undertakings into Impairment of xed assets developed for commercial applications.
The estimated useful lives market risks from treasury operations.
The principal derivative sterling and period end rates to translate the net assets of those The carrying values of xed assets are reviewed for impairment for determining the amortisation charge are reviewed annually, instruments are currency swaps, forward exchange contracts and undertakings.
The currencies which most inuence these when there is an indication that the assets might be impaired.
and take into account the estimated time it takes to bring the interest rate swaps.
The derivative contracts are treated from translations, and the relevant exchange rates, were: Any provision for impairment is charged against profit in the year compounds or products to market as marketable products.
inception as an economic hedge of the underlying financial concerned.
First year impairment reviews are conducted for 2003 2002 2001 Any development costs which are incurred by the Group and instrument, with matching accounting treatment and cash ows.
acquired goodwill and intangible assets.
Certain intangibles are Average rates: are associated with an acquired licence, patent, know-how or The derivative contracts have high correlation with the specic considered to have an indefinite life and are therefore not US$ 1.64 1.50 1.44 marketing rights are written off to the profit and loss account financial instrument being hedged both at inception and amortised.
Such intangibles are subject to annual impairment tests.
Derivative instruments no longer Impairment is determined by reference to the higher of net Yen 191.00 188.00 175.00 designated as hedges are restated at market value and any future Brands are valued independently as part of the fair value of realisable value and value in use, which is measured by reference Period end rates: changes in value are taken directly to the profit and loss account.
businesses acquired from third parties where the brand has a to discounted future cash ows.
The value of shares held by the US$ 1.79 1.61 1.45 value which is substantial and long-term and where the brands Currency swaps and forward exchange contracts used to x the ESOTs is reviewed quarterly to determine if there is any permanent Euro 1.42 1.54 1.64 can be sold separately from the rest of the businesses acquired.
value of the related asset or liability in the contract currency and impairment.
Yen 192.00 192.00 190.00 Brands are amortised over the estimated useful lives but no longer at the contract rate are accrued to the profit and loss account than 20 years, except where the end of the useful economic life over the life of the contract.
of the brand cannot be foreseen.
98 GlaxoSmithKline Notes to the financial statements Notes to the financial statements GlaxoSmithKline 99 5 Merger of Glaxo Wellcome and SmithKline Beecham 6 Segment information continued The combination of Glaxo Wellcome plc and SmithKline Beecham plc was treated as a merger at 27th December 2000 under UK GAAP.
2003 2002 2001 Turnover by location of subsidiary undertaking m m m Under merger accounting, the shares issued by GlaxoSmithKline plc to acquire Glaxo Wellcome and SmithKline Beecham were accounted for at par and no share premium arose: the shares acquired by GlaxoSmithKline in Glaxo Wellcome and SmithKline Beecham were similarly USA 10,569 11,096 10,517 accounted for at the nominal value of the shares issued.
In the consolidated Financial statements of GlaxoSmithKline, the results and net Europe 11,798 10,423 10,704 assets of Glaxo Wellcome and SmithKline Beecham were combined at their book amounts, subject to alignment adjustments.
International 7,945 6,824 7,540 Turnover including inter-segment turnover 30,312 28,343 28,761 6 Segment information USA 219 168 327 An analysis of turnover, profit before taxation, total assets, net assets and tangible xed assets by business and geographical sector are set Europe 4,690 3,873 4,372 out below.
The business sectors consist of Pharmaceuticals prescription pharmaceuticals and vaccines and Consumer Healthcare oral care, International 3,962 3,090 3,573 OTC medicines and nutritional healthcare.
The geographical sectors reect the Groups most significant regional markets and are Inter-segment turnover 8,871 7,131 8,272 consistent with the Groups regional market management reporting structure.
Business sector data includes an allocation of corporate costs USA 10,350 10,928 10,190 to each sector.
There are no sales between business sectors.
Europe 7,108 6,550 6,332 The Groups activities are organised on a global basis.
The geographical sector gures are therefore inuenced by the location of the International 3,983 3,734 3,967 Groups operating resources, in particular manufacturing and research, and by variations over time in intra-Group trading and funding External turnover 21,441 21,212 20,489 arrangements.
Where the Group co-promotes a product and the third party records the sale, the Group records its share of revenue as co-promotion Statutory profit before tax by location of subsidiary undertaking income within turnover.
The nature of co-promotion activities are such that the Group records no costs of sales.
Pharmaceutical turnover USA 1,984 2,117 934 includes co-promotion income of 35 million 2002 nil, 2001 nil.
Europe 3,061 2,490 2,580 International 1,347 944 1,220 2003 2002 2001 Operating profit 6,392 5,551 4,734 Turnover by business sector m m m Share of profits of joint ventures and associated undertakings 93 75 71 Pharmaceuticals 18,181 17,995 17,205 profit on disposal of interest in associate 96 Consumer Healthcare 3,260 3,217 3,284 profit on disposal of businesses 5 10 External turnover 21,441 21,212 20,489 Product divestments 11 296 Net interest payable 161 141 88 Statutory profit before tax by business sector profit before taxation 6,329 5,506 4,517 Pharmaceuticals 5,800 5,068 4,302 profit before taxation 6,329 5,506 4,517 Consumer Healthcare 592 483 432 Taxation 1,739 1,461 1,333 Operating profit 6,392 5,551 4,734 Minority interests 94 110 97 Share of profits of joint ventures and associated undertakings 93 75 71 Preference share dividends 12 20 34 profit on disposal of interest in associate 96 Statutory earnings 4,484 3,915 3,053 profit on disposal of businesses 5 10 Product divestments 11 296 Total assets by location of subsidiary undertaking Net interest payable 161 141 88 USA 4,416 4,455 profit before taxation 6,329 5,506 4,517 Europe 13,106 12,614 International 2,998 2,950 profit before taxation 6,329 5,506 4,517 Taxation 1,739 1,461 1,333 Total operating assets 20,520 20,019 Minority interests 94 110 97 Cash at bank and liquid investments 3,455 2,308 Preference share dividends 12 20 34 Total assets 23,975 22,327 Statutory earnings 4,484 3,915 3,053 Net assets by location of subsidiary undertaking Total assets by business sector USA 515 376 Pharmaceuticals 19,015 18,608 Europe 7,552 7,298 Consumer Healthcare 4,960 3,719 International 2,046 2,049 Total assets 23,975 22,327 Net operating assets 10,113 9,723 Net debt 1,648 2,335 Net assets by business sector Net assets 8,465 7,388 Pharmaceuticals 6,954 5,720 Consumer Healthcare 1,511 1,668 Net assets 8,465 7,388 100 GlaxoSmithKline Notes to the financial statements Notes to the financial statements GlaxoSmithKline 101 6 Segment information continued 2003 2002 7 Merger items, restructuring costs and divested businesses continued Plant, Disposal of Land and equipment Computer Assets in Merger Restructuring Block Drug subsidiaries Total buildings and vehicles software construction Total Total 2003 m m m m m Tangible xed assets by location of subsidiary undertaking m m m m m m Manufacturing and other restructuring 83 83 USA 668 375 50 202 1,295 1,412 Merger integration costs 286 286 Europe 1,580 2,057 109 438 4,184 4,204 Block Drug integration costs 26 26 International 510 341 11 100 962 1,033 Effect on operating profit 286 83 26 395 Total 2,758 2,773 170 740 6,441 6,649 profit on disposal of businesses 5 5 2003 2002 2001 Effect on profit before tax 286 83 26 5 390 Turnover by location of customer m m m USA 10,333 10,807 10,087 Effect on taxation operating items 98 Europe 6,611 6,064 5,855 Effect on taxation non-operating items 11 International 4,497 4,341 4,547 Effect on taxation 109 External turnover 21,441 21,212 20,489 Effect on earnings 281 Disposal of UK segment Merger Restructuring Block Drug subsidiaries Total Information is given separately in respect of the UK, which, although included in the Groups Europe market region, is considered the 2002 m m m m m Groups home segment for the purposes of segmental reporting.
Manufacturing and other restructuring 121 121 Merger integration costs 851 851 2003 2002 2001 Block Drug integration costs 60 60 m m m Effect on operating profit 851 121 60 1,032 Turnover by location of customer 1,404 1,366 1,328 Product divestments 11 11 Turnover including inter-segment turnover 4,678 4,945 5,388 profit on disposal of businesses 10 10 Inter-segment turnover 2,883 3,230 3,753 Effect on profit before tax 840 121 60 10 1,011 Turnover by location of subsidiary 1,795 1,715 1,635 Effect on taxation operating items 266 Operating profit 1,534 1,276 1,772 Effect on taxation non-operating items 33 Total assets 9,889 8,846 Effect on taxation 299 Net operating assets 4,653 4,910 Effect on earnings 712 Disposal of 7 Merger items, restructuring costs and divested businesses Merger Restructuring Block Drug subsidiaries Total 2001 m m m m m Manufacturing and other restructuring costs were incurred by GlaxoSmithKline during 2003, 2002 and 2001 in the implementation of Manufacturing and other restructuring 162 162 previously announced plans for restructuring of manufacturing and other activities.
Merger integration costs 1,069 1,069 Merger integration costs relate to the integration of Glaxo Wellcome and SmithKline Beecham into a unied GlaxoSmithKline business.
Block Drug integration costs 125 125 These costs include consultancy fees in respect of integration planning, severance costs, asset write-offs, costs related to the early vesting Effect on operating profit 1,069 162 125 1,356 or lapse of performance conditions on share options and share incentive awards and costs of the programme to encourage staff to convert Loss on disposal of businesses 296 296 Glaxo Wellcome and SmithKline Beecham share options into GlaxoSmithKline share options.
Integration costs were incurred in 2003, 2002 Effect on profit before tax 1,069 162 125 296 1,652 and 2001 relating to the integration of the Block Drug businesses.
These costs include professional fees, severance costs and asset write-offs.
Effect on taxation operating items 355 Product divestment income arising in 2002 related to the nalisation of the disposals of Famvir, Kytril and other products required in 2000 Effect on taxation non-operating items 33 in order to obtain regulatory approval for the merger.
Effect on taxation 322 The disposal of businesses in 2003 and 2002 related to the nalisation of the disposals of Clinical Laboratories and Healthcare Services in Effect on earnings 1,330 1999.
The disposal of businesses in 2001 primarily arose on the sale of Affymax.
It included a 299 million write off of goodwill which was previously eliminated against Group reserves.
8 Other operating income expense 2003 2002 2001 m m m Royalties and other income 75 75 34 Other operating expense 436 209 126 361 134 92 Income from equity investments and other disposals 228 23 129 133 111 37 Royalties and other income is principally a core of recurring income in the form of royalties from the out-licensing of intellectual property.
Other operating expense includes litigation costs and provisions relating to legal claims on withdrawn products, product withdrawals and anti-trust matters.
Income from equity investments and other disposals includes equity investment carrying value adjustments arising from stock market changes, product disposals and equity investment sales.
102 GlaxoSmithKline Notes to the financial statements Notes to the financial statements GlaxoSmithKline 103 11 Net interest payable 2003 2002 2001 9 Operating profit 2003 2002 2001 m m m m m m The following items have been charged in operating profit: Interest payable Employee costs Note 33 5,058 4,940 4,686 On bank loans and overdrafts 6 6 26 Advertising 615 688 696 On other loans 186 198 169 Distribution costs 284 281 272 In respect of finance leases 2 2 3 Depreciation of tangible xed assets: Unwinding of discount on provisions 20 Owned assets 771 760 758 214 206 198 Leased assets 2 4 3 Share of interest payable of associate 8 8 19 Amortisation of goodwill 13 12 10 222 214 217 Amortisation of intangible xed assets 74 60 40 Investment income Exchange losses on foreign currency deposits loans 1 Interest income 58 71 129 Operating lease rentals: Realised gains 2 Plant 90 50 41 Unwinding of discount on assets 3 Land and buildings 62 61 70 Audit fees 6.9 6.1 7.2 61 73 129 Fees to auditors for other work: 161 141 88 Auditors UK rm 1.7 5.2 13.1 Auditors overseas rms 5.9 9.6 22.6 12 Taxation Analysis of fees to auditors for other work: Further assurance audit-related services 2.6 1.8 2003 2002 2001 Taxation charge based on profits for the period m m m Tax services 4.6 4.9 Merger of Glaxo Wellcome and SmithKline Beecham 6.0 UK corporation tax at the UK statutory rate 673 479 838 Other services 0.4 2.1 Less double taxation relief 290 117 351 383 362 487 Included within audit fees above is a fee of 10,000 2002 10,000, 2001 10,000 relating to the company audit of Overseas taxation 1,578 1,036 876 GlaxoSmithKline plc.
Included in further assurance services in 2003 are amounts related to the Groups preparation for the adoption Deferred taxation 262 29 53 of International Financial Reporting Standards and preparation for section 404 of the Sarbanes-Oxley Act 2002.
Tax services relates 1,699 1,427 1,310 to fees paid for corporate tax compliance, tax planning and advice.
Other services include human resources advisory, compliance and Share of taxation charge of associates 40 34 23 treasury related services.
Included within fees to auditors for other work in 2002 is 6.0 million paid to the auditors management consulting practice, which was sold by them in 2002.
1,739 1,461 1,333 In 2003, the Group has started to apply discounting to certain long-term assets and liabilities, using risk-free rates of return.
2003 2002 2001 Reconciliation of the current taxation rate on Group profits % % % 10 Joint ventures and associated undertakings 2003 2002 2001 UK statutory rate of taxation 30.0 30.0 30.0 m m m Overseas taxes 0.1 0.1 1.1 Associated undertakings: Average Group tax rate 30.1 30.1 28.9 Share of profits of Quest Diagnostics Inc. 102 94 79 Effect of special tax status in manufacturing locations 3.9 3.9 3.7 Share of losses of other associated undertakings 3 1 Share option deductions in the USA 0.1 0.2 1.1 Amortisation of goodwill 6 6 7 Merger and restructuring costs 0.1 0.7 5.4 93 88 71 R&D credits 1.1 1.2 0.9 Other permanent differences 1.1 0.8 0.4 Share of losses of joint ventures 13 Capital allowances in excess of depreciation 0.3 0.5 93 75 71 Intra-Group profit 0.1 1.3 1.3 Reversing timing differences on tax losses 2.5 Share of turnover of joint ventures 31 29 28 Other timing differences 3.9 2.3 3.9 Sales to joint ventures and associated undertakings 51 49 52 Prior year items 1.5 2.4 0.7 Current tax rate on ordinary activities 31.0 25.4 30.2 Capital allowances in excess of depreciation 0.3 0.5 Intra-Group profit 0.1 1.3 1.3 Reversing timing differences on tax losses 2.5 Other timing differences 3.9 2.3 3.9 Share of taxation charge of associates 0.6 0.6 0.5 Prior year items 0.6 3.6 1.5 Tax rate on ordinary activities 27.5 26.5 29.5 The Group operates in countries where the tax rate differs from the UK tax rate.
The average Group tax rate has been determined by aggregating the local standard tax rates and weighting these in proportion to accounting profits.
profits arising from manufacturing operations in Singapore, Puerto Rico and Ireland are taxed at reduced rates.
The effect of this reduction in the taxation charge increased earnings per share by 4.2p in 2003, 3.6p in 2002 and by 2.7p in 2001.
104 GlaxoSmithKline Notes to the financial statements Notes to the financial statements GlaxoSmithKline 105 12 Taxation continued 13 Earnings per share 2003 2002 2001 The integrated nature of the Groups worldwide operations, involving significant investment in research and strategic manufacture at a p p p limited number of locations, with consequential cross-border supply routes into numerous end-markets, gives rise to complexity and delay Basic earnings per share 77.2 66.2 50.3 in negotiations with revenue authorities as to the profits on which individual Group companies are liable to tax.
Disagreements with, and Adjustment for merger items, restructuring costs and disposal of subsidiaries: between, revenue authorities as to intra-Group transactions, in particular the price at which goods should be transferred between Group Merger integration and transaction costs 3.8 10.8 13.0 companies in different tax jurisdictions, can produce conicting claims from revenue authorities as to the profits that fall to be taxed in Restructuring costs 1.0 1.5 2.0 individual territories.
Resolution of such issues is a continuing fact of life for GlaxoSmithKline.
The Group has open issues with the revenue Block Drug integration costs 0.3 0.7 1.6 authorities in the USA, UK, Japan and Canada, but by far the largest relates to Glaxo heritage products in the USA.
Disposal of businesses 0.2 0.9 5.4 GlaxoSmithKline has attempted to settle the US dispute, first through direct discussion with the US Internal Revenue Service IRS and Adjusted earnings per share 82.1 78.3 72.3 subsequently through discussions between the US and UK authorities under the terms of the double tax convention between the two countries.
GlaxoSmithKline understands that the views of the two tax authorities were so different that they were unable to reach Diluted earnings per share 77.0 66.0 49.9 agreement, and discussions were terminated in July 2003.
Basic and adjusted earnings per share have been calculated by dividing the profit attributable to shareholders by the weighted average The Group has now received a claim for additional taxes that the IRS asserts legacy company Glaxo Wellcome owes for the years 1989 to number of shares in issue during the period.
The numbers used in calculating basic and diluted earnings per share are reconciled below.
This statutory notice of deficiency for $2.7 billion 1.5 billion in tax principally relates to the allocation of profits for Glaxo heritage Adjusted earnings per share is calculated using business performance earnings.
Business performance, which is the primary performance products between the USA and other countries.
To the extent that the IRS were successful in its claim, interest would be payable.
measure used by management, is presented after excluding merger items, integration and restructuring costs and the disposal of businesses.
GlaxoSmithKline estimates the interest on the full claim to date would be approximately $2.5 billion 1.4 billion, net of federal tax relief.
Management believes that exclusion of these items provides a better reection of the way in which the business is managed and gives an As similar tax issues remain open for 1997 to date, GlaxoSmithKline expects to receive further claims by the IRS for these years.
indication of the performance of the Group in terms of those elements of revenue and expenditure which local management is able to Since GlaxoSmithKline has exhausted all administrative remedies open to it, the Group plans to contest this claim for additional taxes inuence.
This information, which is provided in addition to the statutory results prepared under UK GAAP, is given to assist shareholders by ling a petition in the US Tax Court, where a trial is not expected until sometime in 2005 or 2006. to gain a clearer understanding of the underlying performance of the business and to increase comparability for the periods presented.
GlaxoSmithKline continues to believe that the profits reported by its US subsidiaries for the period 1989 to date, on which it has paid taxes Net profit for the period attributable to shareholders m m m in the USA, are more than sufficient to reect the activities of its US operations.
Earnings basic and diluted 4,484 3,915 3,053 GlaxoSmithKline uses the best advice in determining its transfer pricing methodology and in seeking to manage transfer pricing issues to Adjustments for merger items, restructuring costs and disposal of subsidiaries 281 712 1,330 a satisfactory conclusion and, on the basis of external professional advice, continues to believe that it has made adequate provision for the Adjusted earnings 4,765 4,627 4,383 liabilities likely to arise from open assessments.
However, there continues to be a wide difference of views between the Group and the IRS.
The ultimate liability for such matters may vary from amounts provided and is dependent upon the outcome of litigation proceedings and negotiations with the relevant tax authorities.
Weighted average number of shares in issue millions millions millions Except as shown in these Financial statements, no provision has been made for taxation which would arise on the distribution of profits Basic and adjusted 5,806 5,912 6,064 retained by overseas subsidiary and associated undertakings, on the grounds that no remittance of profit retained at 31st December 2003 Dilution for share options 18 22 52 is required in such a way that incremental tax will arise.
Diluted 5,824 5,934 6,116 At 31st December 2003, the Group had income tax losses of approximately 225 million 2002 69 million and capital losses estimated to be in excess of 10 billion 2002 in excess of 9 billion which are not recognised as deferred tax assets because there is insufficient Shares held by the Employee Share Ownership Trusts ESOTs are excluded.
The trustees have waived their rights to dividends on the shares evidence that these losses will be used.
Current Deferred Deferred tax creditor tax debtor tax provision 14 Dividends 2003 2002 2001 Tax balances m m m m m m At 1st January 2003 1,449 1,373 742 First interim 524 535 546 Exchange adjustments 112 64 11 Second interim 522 530 546 Charge to profit and loss account 1,961 122 140 Third interim 520 527 546 Cash paid 1,917 Fourth interim 808 754 718 Other movements 77 10 7 2,374 2,346 2,356 At 31st December 2003 1,458 1,441 606 2003 2002 2001 Dividends per share p p p 2003 2002 Deferred taxation asset liability m m First interim 9 9 9 Second interim 9 9 9 Accelerated capital allowances 689 710 Third interim 9 9 9 Stock valuation adjustment 52 113 Fourth interim 14 13 12 Intra-Group profit 485 487 Product and business disposals 59 125 41 40 39 Pensions and other post-retirement benets 113 190 Tax losses 94 93 Legal and other disputes 167 124 Merger integration and manufacturing restructuring 157 204 Other net timing differences 619 481 835 631 Deferred taxation provided on stock valuation adjustments, intra-Group profit and other timing differences shown above are current.
All deferred taxation movements arise from the origination and reversal of timing differences.
Other net timing differences include accrued expenses and other provisions.
106 GlaxoSmithKline Notes to the financial statements Notes to the financial statements GlaxoSmithKline 107 Plant, Land and equipment Computer Assets in 15 Goodwill Total 17 Tangible xed assets buildings and vehicles software construction Total m m m m m m Cost at 1st January 2003 216 Cost at 1st January 2003 4,310 6,714 332 1,027 12,383 Exchange adjustments 23 Exchange adjustments 63 66 3 46 178 Additions Note 31 2 Additions 45 213 11 601 870 Disposals 168 471 3 29 671 Cost at 31st December 2003 195 Reclassications 125 816 94 785 Amortisation at 1st January 2003 45 Cost at 31st December 2003 3,999 7,206 431 768 12,404 Exchange adjustments 6 Provision for the year 13 Depreciation at 1st January 2003 1,258 3,950 172 5,380 Exchange adjustments 23 70 1 94 Amortisation at 31st December 2003 52 Provision for the year 121 583 69 773 Disposals 86 345 1 432 Net book value at 1st January 2003 171 Reclassications 158 158 Net book value at 31st December 2003 143 Depreciation at 31st December 2003 1,112 4,276 239 5,627 Impairment at 1st January 2003 148 182 24 354 Licences, Exchange 3 2 5 16 Other intangible assets patents, etc.
Brands Total m m m Impairment loss 19 24 22 4 69 Disposals 35 47 82 Cost at 1st January 2003 712 1,162 1,874 Exchange adjustments 29 7 22 Impairment at 31st December 2003 129 157 22 28 336 Additions 193 193 Total depreciation and impairment at 31st December 2003 1,241 4,433 261 28 5,963 Assets written off 38 38 Net book value at 1st January 2003 2,904 2,582 160 1,003 6,649 Cost at 31st December 2003 838 1,169 2,007 Net book value at 31st December 2003 2,758 2,773 170 740 6,441 Amortisation at 1st January 2003 162 162 Exchange adjustments 5 5 The net book value at 31st December 2003 of the Groups land and buildings comprises freehold properties 2,532 million Provision for the year 74 74 at 1st January 2003 2,699 million, properties with leases of 50 years or more 182 million at 1st January 2003 135 million and Assets written off 2 2 properties with leases of less than 50 years 44 million at 1st January 2003 70 million.
Included in plant, equipment and vehicles at 31st December 2003 are leased assets with a cost of 3 million at 1st January 2003 6 million, accumulated depreciation of 2 million Amortisation at 31st December 2003 229 229 at 1st January 2003 4 million and a net book value of 1million at 1st January 2003 2 million.
Impairment at 1st January 2003 53 22 75 The impairment loss principally arises from decisions to rationalise facilities and is calculated based on either net realisable value or value Exchange adjustments 3 2 1 in use, typically using, which has been recorded in SG&A, a discount rate of eight per cent.
Impairment loss 8 3 11 Assets written off 6 6 Joint Associated Equity Own 18 Fixed asset investments ventures undertakings investments shares Total Impairment at 31st December 2003 58 23 81 m m m m m Total amortisation and impairment at 31st December 2003 287 23 310 At 1st January 2003 17 153 125 2,826 3,121 Exchange adjustments 2 17 9 28 Net book value at 1st January 2003 497 1,140 1,637 Additions 4 33 37 Charge for the year 25 25 Net book value at 31st December 2003 551 1,146 1,697 Impairment 32 32 Transfers 15 15 The licences and patents acquired in the year relate to the acquisition of various compound rights and other research based agreements Disposals 2 4 26 32 see Note 26.
Retained profit for the year 34 34 Brands largely comprise a portfolio of products acquired with the acquisition of Sterling Winthrop Inc. in 1994, such as Panadol, Solpadeine Goodwill amortisation 6 6 and Hedex, and the products acquired with the acquisition of The Block Drug Company in 2001, such as Sensodyne, Polident and Poligrip.
At 31st December 2003 13 183 98 2,775 3,069 Each of these is considered to have an indefinite life given the strength and durability of the brand and the level of marketing support.
Accordingly, they are not amortised.
The valuation of each Sterling brand is reviewed annually using a 10 year cash ow forecast as this Investments in joint ventures comprise 15 million share of gross assets 2002 19 million and 2 million share of gross liabilities 2002 2 million.
was the basis for the original independent assessment when they were acquired in 1994 and a post-tax discount rate of eight per cent.
The principal associated undertaking is Quest Diagnostics, Inc. a US clinical laboratory business listed on the New York Stock Exchange.
The valuation of each Block Drug brand is also reviewed annually using a five year cash ow forecast and a post-tax discount rate of The investment has a book value at 31st December 2003 of 158 million 2002 129 million and a market value of 904 million eight per cent.
At 31st December 2003, the Group owned 21 per cent of Quest 2002 23 per cent.
The book value includes goodwill which is being amortised over 20 years: the amortisation charge for 2003 was 6 million.
The goodwill at 31st December 2003 amounts to 85 million 2002 101 million.
Goodwill of 103 million which relates to the continuing Group interest in Clinical Laboratories assets attributed to Quest, remains eliminated against Group reserves.
Equity investments comprise listed investments of 7 million 2002 7 million and unlisted investments of 91 million 2002 118 million.
The market value of listed investments at 31st December 2003 was 9 million 2002 11 million.
Investments in own shares consist of shares held by Employee Share Ownership Trusts see Note 34.
The market value of own shares at 31st December 2003 was 2,276 million 2002 2,161 million.
This valuation shortfall is not considered to represent a permanent diminution in value in the context of the length of the future period over which the related share options may be exercised.
Accordingly no provision has been made.
108 GlaxoSmithKline Notes to the financial statements Notes to the financial statements GlaxoSmithKline 109 Pensions and other Legal 19 Equity investments 23 Provisions for post-retirement Manufacturing Merger and other Deferred Other Total liabilities and charges benets restructuring integration disputes taxation provisions Total m m m m m m m m At 1st January 2003 161 At 1st January 2003 921 103 403 507 742 157 2,833 Exchange adjustments 9 Exchange adjustments 48 4 5 74 11 4 124 Additions 37 Charge for the year 239 49 76 570 140 148 942 Impairments 7 Unwinding of discount 7 12 1 20 Disposals 32 Applied 305 49 184 239 42 819 At 31st December 2003 164 Reclassications and other movements 8 231 7 54 178 At 31st December 2003 807 99 305 1,007 606 206 3,030 Equity investments include listed investments of 111 million 2002 125 million.
The market value of listed investments was 184 million 2002 232 million.
During 2003, the Group made special cash contributions totalling 368 million into the UK and US pension schemes.
The contribution relating to the US pension scheme is included within the amounts applied to the provision above: the contributions relating to the UK pension scheme have increased the pension prepayment amount shown under debtors in Note 21.
20 Stocks 2003 2002 m m The Group has recognised costs in 2003 in respect of plans for manufacturing and other restructuring initiated in 1998, 1999 and in 2001 Raw materials and consumables 636 508 following the merger of Glaxo Wellcome and SmithKline Beecham and acquisition of Block Drug.
These plans are largely completed.
Costs Work in progress 474 673 recognised as a provision, principally in respect of identied severances at sites where it has been announced that manufacturing activities Finished goods 999 899 will cease, are expected to be incurred mainly in 2004.
Costs of asset write-downs have been recognised as an impairment of xed assets.
2,109 2,080 The Group has recognised costs in 2003, 2002 and 2001 in respect of plans for the integration of the Glaxo Wellcome and SmithKline Beecham businesses.
Implementation of the integration following the merger is substantially complete.
Costs recognised as a provision in respect of identied severances are expected to be incurred in 2004 and in respect of the programme to encourage staff to convert Glaxo Wellcome or SmithKline Beecham share options into GlaxoSmithKline share options when employees exercise these options up to 2010.
21 Debtors 2003 2002 This latter provision was discounted by 28 million in 2003 using risk-free rates of return.
m m Provisions for legal and other disputes and other matters include amounts relating to US anti-trust, product liability, contract terminations, Amounts due within one year self-insurance, environmental clean-up and property rental.
The companys Directors, having taken legal advice, have established provisions Trade debtors 3,715 3,515 after taking into account insurance and other agreements and having regard to the relevant facts and circumstances of each matter and Other debtors 532 569 in accordance with accounting requirements.
These provisions were discounted by 25 million in 2003 using risk-free rates of return.
Prepaid pension contributions 440 257 Reclassications include amounts receivable under insurance contracts which are now shown within Other debtors in Note 21.
No Other prepayments and accrued income 247 178 provisions have been made for unasserted claims.
The ultimate liability for such matters may vary from the amounts provided and is Amounts due after one year dependent upon the outcome of litigation proceedings, investigations and possible settlement negotiations.
Other debtors 512 294 GlaxoSmithKline is involved in a number of legal and other disputes including notication of possible claims where, because of the early Prepayments and accrued income 10 14 stage of the matter, no reliable estimate of the outcome can be made.
Accordingly no provision has been recorded for these matters or Deferred taxation Note 12 1,441 1,373 any unasserted claims.
6,897 6,200 It is in the nature of the Groups business that a number of these matters may be the subject of negotiation and litigation over several Debtors include trading balances of 1 million 2002 nil due from joint ventures and associated undertakings.
Other debtors due after years.
The largest individual amounts provided are expected to be settled within three years.
one year include insurance recovery receivables which have been discounted using a risk-free rate of return.
For a discussion of legal issues, refer to Note 30, Legal proceedings.
24 Contingent liabilities 22 Other creditors 2003 2002 m m At 31st December 2003 contingent liabilities, comprising guarantees, discounted bills and other items arising in the normal course of Amounts due within one year business, amounted to 236 million 2002 138 million.
For a discussion of tax issues, refer to Note 12, Taxation and of legal issues, Trade creditors 686 715 refer to Note 30, Legal proceedings.
Taxation Note 12 1,458 1,449 Social security 108 87 Other creditors 439 429 Accruals and deferred income 3,121 3,285 Dividends payable 1,333 1,292 7,145 7,257 Amounts due after one year Other creditors 130 113 Accruals and deferred income 102 93 232 206 Accruals include obligations for wages and salaries of 689 million 2002 557 million.
110 GlaxoSmithKline Notes to the financial statements Notes to the financial statements GlaxoSmithKline 111 25 Net debt continued 25 Net debt 2003 2002 m m Secured loans Liquid investments 2,493 1,256 Loans amounting to 13 million 2002 13 million are secured by charges on xed and current assets.
Cash at bank 962 1,052 2003 2002 Finance lease obligations m m 3,455 2,308 Rental payments due within one year 1 1 Loans and overdrafts due within one year: Rental payments due between one and two years 2 2 Bank loans and overdrafts 230 263 Rental payments due between two and three years 1 1 Commercial paper 836 1,284 Rental payments due between three and four years 1 1 Eurobonds and Medium-Term notes 383 Rental payments due between four and five years 2 1 Obligations under finance leases 1 1 Rental payments due after five years 6 7 Other loans 2 3 Total finance lease obligations 13 13 1,452 1,551 Loans due after one year: Financial instruments Bank loans 4 3 Further information is given in Note 32.
Eurobonds, Medium-Term notes and private nancing 3,617 3,054 Loan Stock 13 14 26 Commitments Obligations under finance leases 12 12 2003 2002 Other loans 5 9 Capital commitments m m 3,651 3,092 Contracted for but not provided in the financial statements: Net debt 1,648 2,335 Intangible xed assets 1,412 1,410 Tangible xed assets 171 382 At the balance sheet date the Groups liquid investments had an aggregate market value of 2,509 million 2002 1,264 million.
1,583 1,792 Liquid investments include redeemable preference shares, which are fully collateralised with highly rated bonds, of 1 billion 2002 nil.
The Group has entered into a number of research collaborations to develop new compounds with other pharmaceutical companies.
The terms of these arrangements can include up-front fees, equity investments, loans and commitments to fund specified levels of research Loans and overdrafts due within one year in the future.
In addition the Group will often agree to make further payments if future milestones are achieved.
As some of these Commercial paper comprises a US$10 billion programme, of which 836 million was in issue at 31st December 2003 agreements relate to compounds in the early stages of development, milestone payments will continue for a number of years if the 31st December 2002 1,284 million, backed up by committed facilities of 364 days duration of 784 million 2003 $1,404 million: compounds move successfully through the development process.
Generally the closer the product is to marketing approval the greater 2002 $1,404 million, renewable annually, and liquid investments of 708 million 2003 $1,267 million: 2002 $1,267 million.
The weighted average interest rate on commercial paper borrowings at 31st December 2003 was 1.1 per cent 2002 1.3 per cent.
The Group also has other commitments of 144 million 2002 162 million relating to revenue payments to be made under licences and other alliances, principally to Exelixis Inc. Loans due after one year In 2003 two bonds were issued under the European Medium Term Note programme: a 1 billion, 3.375 per cent coupon bond and a A number of commitments were made in 2003 under licensing and other agreements, principally with NeuroSearch A S, Ranbaxy 500 million, 3.25 per cent coupon bond.
Laboratories Ltd. and POZEN Inc. Loans due after one year are repayable over various periods as follows: 2003 2002 2003 2002 Commitments under operating leases to pay rentals for the next year m m m m Operating leases on land and buildings which expire: Between one and two years 562 423 In one year or less 6 10 Between two and three years 281 563 Between one and five years 19 47 Between three and four years 2 311 After five years 35 56 Between four and five years 1,199 2 60 113 After five years 1,607 1,793 Operating leases on plant, equipment and vehicles which expire: 3,651 3,092 In one year or less 8 7 The loans repayable after five years carry interest at effective rates between 3.3 per cent and 5.3 per cent.
The repayment dates range from Between one and five years 50 47 2009 to 2033.
After five years 2 1 60 55 Commitments under operating leases to pay rentals in future years 2004 120 168 2005 94 97 2006 78 80 2007 54 59 2008 43 49 2009 and thereafter 158 249 547 702 112 GlaxoSmithKline Notes to the financial statements Notes to the financial statements GlaxoSmithKline 113 Other profit and Share 29 Reserves reserves loss account Total premium m m m Ordinary Shares of 25p each 27 Share capital and share premium account account At 31st December 2000 1,849 4,155 6,004 Number m m Goodwill written back 356 356 Share capital authorised Exchange movements 151 151 At 31st December 2002 10,000,000,000 2,500 Shares purchased for cancellation 17 1,274 1,257 At 31st December 2003 10,000,000,000 2,500 profit attributable to shareholders 3,053 3,053 Dividends 2,356 2,356 Share capital issued and fully paid Revaluation of goodwill due to exchange 28 28 At 1st January 2002 6,172,965,989 1,543 170 Share capital issued under share option schemes 7,049,394 2 54 At 31st December 2001 1,866 3,811 5,677 Share capital purchased and cancelled 155,749,038 39 Exchange movements 154 154 UK tax on exchange movements 67 67 At 31st December 2002 6,024,266,345 1,506 224 Shares purchased for cancellation 39 2,220 2,181 Share capital issued under share option schemes 6,041,283 1 40 profit attributable to shareholders 3,915 3,915 Share capital purchased and cancelled 80,844,000 20 Dividends 2,346 2,346 At 31st December 2003 5,949,463,628 1,487 264 Unrealised gains on equity investments 7 7 At 31st December 2002 1,905 2,946 4,851 Number 000 Exchange movements 37 37 Number of shares issuable under outstanding options Note 34 Tax on exchange movements and unrealised gains 69 69 At 31st December 2002 217,953 Shares purchased for cancellation 20 980 960 At 31st December 2003 259,990 profit attributable to shareholders 4,484 4,484 Dividends 2,374 2,374 Number of unissued shares not under option Unrealised gains on equity investments 7 7 At 31st December 2002 3,757,781 Revaluation of goodwill due to exchange 7 7 At 31st December 2003 3,790,546 At 31st December 2003 1,925 4,044 5,969 In October 2002, GlaxoSmithKline commenced a new 4 billion share buy-back programme.
This follows the completion of the 4 billion Goodwill arising on acquisitions before 1st January 1998 which has been written off against other reserves amounts to 6,180 million, buy-back programme announced in 2001.
A total of 1,199 million has been spent on the new share buy-back programme, of which including goodwill of 4,840 million previously held as a goodwill reserve which was offset against other reserves in 1998.
The goodwill 980 million was spent in 2003.
The exact amount and timing of future purchases, and whether some repurchased shares will be held as written back in 2001 relates primarily to the disposals of Affymax and part of the Groups holding in Quest Diagnostics, Inc.
Goodwill Treasury shares rather than being cancelled, will be determined by the company and is dependent on market conditions and other factors.
denominated in local currencies which is subject to revaluation amounted to 300 million at 31st December 2003.
In the period 1st January 2004 to 27th February 2004 a further 5 million shares have been purchased and cancelled at a cost of 55 million.
Goodwill on acquisitions after 1st January 1998 has been capitalised, in accordance with the accounting policy set out in Note 2.
For details of substantial shareholdings refer to Substantial shareholdings on page 162.
Exchange movements taken to reserves in 2003 include losses of 103 million 2002 losses 1,251 million, 2001 losses 114 million on foreign currency loans less deposits, gains of 133 million 2002 gains 1,097 million, 2001 losses 9 million on the 28 Non-equity minority interests retranslation of net assets and 7 million 2002 nil, 2001 losses 28 million on goodwill eliminated against reserves.
SmithKline Beecham Holdings Corporation SBH Corp, a subsidiary incorporated in Delaware, USA, has in issue $500 million of Flexible The tax on exchange movements and unrealised gains in the year of 69 million 2002 67 million, 2001 nil relates to the taxable Auction Market Preferred Stock Flex AMPS, comprising 5,000 shares of $100,000 each, issued in six series.
The dividend on these shares element of the foreign currency loans less deposits and unrealised gains taken to reserves.
was xed on issuance in 1996 for a seven-year period that ended in July 2003 for half of the shares and for a five year period which Exchange adjustments debited to reserves cumulatively amount to 1,415 million 2002 1,452 million, 2001 1,298 million.
ended during 2001 for the other half.
The dividend for all these shares now varies, predominately with prevailing interest rates, and is set every seven weeks at an auction at which the shares are also traded.
Other reserves include the merger reserve created on the merger of Glaxo Wellcome and SmithKline Beecham amounting to 1,561 million at 31st December 2003 2002 1,561 million: 2001 1,561 million.
Other reserves also include the capital redemption reserve created SBH Corp also has in issue $400 million of Auction Rate Preference Stock ARPS, comprising 4,000 shares of $100,000 each, issued in as a result of the share buy-back programme amounting to 76 million at 31st December 2003 2002 56 million, 2001 17 million.
five series, the dividend on which also varies under conditions similar to the Flex AMPS described above.
Total reserves amounted to 5,969 million at 31st December 2003 2002 4,851 million, 2001 5,677 million, of which 8,981 million Together, the ARPS and the Flex AMPS constitute the preference shares, which represent the non-equity minority interests.
Notice to 2002 10,879 million: 2001 718 million relates to the company and 86 million 2002 76 million, 2001 61 million relates to redeem all eleven series was given in February 2004, with redemption expected to be completed in March and April 2004. joint ventures and associated undertakings.
SmithKline Beecham plc has, in certain circumstances, guaranteed payment of dividends declared on the preference shares.
SmithKline The profit of GlaxoSmithKline plc for the year was 1,436 million 2002 10,598 million, 2001 - 4,331 million, which after dividends Beecham plc has also agreed with SBH Corp that in certain circumstances it will provide support to SBH Corp in relation to the principal.
of 2,374 million 2002 2,352 million, 2001 2,356 million, gave a retained loss of 938 million 2002 profit of 8,246 million, However, any guarantee or support is limited so that in no circumstances could the holder of preference shares be in a more favourable 2001 profit of 1,975 million.
After the cost of shares purchased for cancellation of 980 million 2002 2,220 million, position than had they been a holder of a preference share in SmithKline Beecham plc.
The preference shares represent a long-term 2001 1,274 million and an unrealised profit on capital reduction by subsidiary of nil 2002 4,096 million, 2001 nil, the profit non-equity minority interest in the Group balance sheet in accordance with FRS 4 Capital Instruments and UITF 33 Obligations in capital and loss account reserve at 31st December 2003 stood at 8,905 million 2002 10,823 million, 2001 701 million, of which instruments.
